AbbVie Inc. is making a significant commitment to North Carolina with plans to establish a new manufacturing campus in Durham. This ambitious project, which amounts to an investment of $1.4 billion, will span 185 acres and is designed to integrate cutting-edge manufacturing techniques and laboratory technologies using artificial intelligence (AI). The facility will focus on the production of AbbVie’s medicines in immunology, neuroscience, and oncology, marking the company’s first substantial investment in this region. Construction is slated to commence this year, with an anticipated completion by the end of 2028.
Strategic Location and Workforce
The choice of Durham, situated near Research Triangle Park, underscores AbbVie’s recognition of the region’s robust workforce and its capacity for future growth. Upon completion, this campus will become AbbVie’s U.S. center of excellence for small volume parenteral (SVP) manufacturing, facilitating the delivery of next-generation therapies to patients both domestically and internationally.
Robert A. Michael, AbbVie’s Chairman and CEO, emphasized the importance of this investment as a landmark moment for the company. He noted that this expansion not only enhances AbbVie’s manufacturing capabilities but also fosters job creation and strengthens ties with the local community and the state.
Job Creation and Economic Impact
Over the next four years, AbbVie plans to recruit nearly 750 professionals, including engineers, scientists, manufacturing operators, and laboratory technicians. Additionally, the construction phase of the project will generate over 2,000 jobs, significantly contributing to the local economy.
This initiative is part of AbbVie’s broader commitment of $100 billion towards research and development (R&D) and capital investments in the United States over the next decade. The first construction phase will focus on facilities for SVP drug product manufacturing, advanced laboratories, warehousing, administrative offices, and wellness facilities for employees, with ample space to accommodate AbbVie’s expanding pipeline of therapies.
State and Local Support
North Carolina Governor Josh Stein welcomed AbbVie’s substantial investment, highlighting the state’s reputation for research and innovation, which, combined with its thriving life sciences sector, positions it as a prime destination for biopharmaceutical enterprises.
Lee Lilley, the N.C. Commerce Secretary, noted that AbbVie’s decision further solidifies North Carolina’s standing in the global life sciences arena. He reaffirmed the state’s commitment to nurturing a skilled workforce, infrastructure, and an ecosystem capable of delivering essential medicines to patients worldwide.
Economic Development Grant and Infrastructure Support
The site selected in Durham County falls under the state’s Tier 3 economic classification. As part of the Job Development Investment Grant (JDIG) agreement, AbbVie will contribute up to $6.44 million to the state’s Industrial Development Fund – Utility Account. This fund supports rural communities in financing infrastructure improvements necessary to attract future businesses.
Christopher Chung, CEO of the Economic Development Partnership of North Carolina, praised AbbVie’s investment as a testament to the thriving life sciences ecosystem in the state. He emphasized that North Carolina’s skilled talent pool and robust manufacturing capabilities make it a top choice for companies aiming for growth.
Growing Life Sciences Sector
In 2025, AbbVie spent $538 million with 361 suppliers within North Carolina, reflecting the strong ties the company has developed with local businesses. The state is home to more than 860 life sciences companies, employing over 76,000 individuals in the sector, showcasing its growing significance in the biopharmaceutical landscape.
Conclusion
AbbVie’s investment in North Carolina represents a pivotal moment for both the company and the region, promising job creation and economic growth. As the life sciences sector continues to flourish, this new facility is poised to enhance AbbVie’s capabilities while solidifying North Carolina’s position as a leader in biopharmaceutical innovation.
- AbbVie is investing $1.4 billion in a new Durham campus.
- The facility will integrate AI with advanced manufacturing for drug production.
- Nearly 750 jobs will be created, with over 2,000 construction jobs.
- The project supports North Carolina’s growing life sciences sector.
- AbbVie’s investment is part of a broader $100 billion commitment to U.S. R&D.
Read more → businessfacilities.com